Kyverna Therapeutics is a clinical-stage biotechnology company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. Co. platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. The KYTX average annual return since 2024 is shown above.
The Average Annual Return on the KYTX average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KYTX average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KYTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|